The research progress of immunotherapy in head and neck squamous cell carcinoma / 天津医药

ABSTRACT

Despite the continuous progress and development of surgical and comprehensive treatment in recent years, the 5-year survival rate of patients with head and neck squamous cell carcinoma (HNSCC) has not been significantly improved.Therefore,improving treatment efficiency and therapeutic strategies are urgently needed.As one promising novel therapy,immunotherapy has been gradually applied in the treatment of multiple tumors including HNSCC with low toxicity and high specificity.In the immunotherapy of HNSCC,the researchers have further developed a combined systemic therapy from single cytokine therapy and achieved good effects. On the other hand, multiple cancer vaccine therapies including protein/polypeptide-dendritic cell vaccine have been put into clinical trials.In addition,immunotherapy against PD-1 and other immune checkpoints have received extensive attention,and relevant inhibitory antibodies have also been approved for the treatment of recurrent or metastatic HNSCC. Here, we briefly make a review about the progress of multiple immunotherapies for the treatment of HNSCC,including cytokine therapy,vaccine therapy and immune checkpoint therapy.